Lanthanide, zirconium, and zinc MOF frameworks engineered for tunable visible and NIR emission — solving aggregation-induced quenching, narrow color range, and stability limitations that constrain current OLED materials.
The global OLED market exceeds $50B and is growing rapidly across consumer electronics, automotive displays, AR/VR headsets, medical devices, and flexible screens. Current small-molecule and polymer OLED emitters face three critical limitations that MOF-based luminescent platforms solve simultaneously.
The CWY005 patent covers six distinct luminescent MOF formula families, each engineered for different emission profiles, charge transport roles, and device integration requirements.
Lanthanide f-f electronic transitions produce sharp, narrow emission lines with high color purity — ideal for display applications requiring precise primary colors. High quantum efficiency from antenna effect: organic linker absorbs excitation energy and transfers to lanthanide ion. Eu(III) emits red at 615 nm; Tb(III) green at 545 nm; Yb(III) and Nd(III) emit in the NIR for bioimaging and telecommunications.
Bimetallic lanthanide MOFs incorporating two different lanthanide ions in a single framework emit at two independent wavelengths simultaneously. Eu/Tb combinations produce tunable red-green emission enabling white light generation from a single material — eliminating the multi-layer architectures required for conventional white OLEDs. Phosphorescence + fluorescence combined for broader spectral coverage. Emission ratio tunable by adjusting metal stoichiometry.
High structural robustness and exceptional chemical stability (500°C thermal limit, acid/base resistant). Tunable luminescence via organic linker selection without altering the Zr₆ secondary building unit. Efficient charge transport — functions as both emissive layer and electron transport layer (ETL) in device stack. Low toxicity vs heavy-metal OLED emitters. 14 carboxylate linker variants including BDC, NDC, and TPDC derivatives.
Strong luminescence from conjugated organic linkers with Zn(II) coordination. Functions as electron transport layer (ETL) or hole blocker in device architectures. Host-guest interactions: phosphorescent or fluorescent dye molecules encapsulated in MOF pores achieve enhanced quantum efficiency through reduced concentration quenching. Guest loading tunable without changing framework structure. Particularly effective for flexible and foldable display applications.
The CWY005 platform addresses four distinct commercial markets, each with independent buyer profiles and licensing timelines.
CWY005 is a non-provisional US patent application filed in 2024, covering all six luminescent MOF formula families. It is independently licensable — entirely separate from the drug delivery and carbon capture families — with its own buyer profile and timeline.
Filed 2024 under Viva Bio LLC (Delaware). All six formula families covered under a single patent application with independent claims per family.
Each formula family independently licensable. Exclusive licensing by application vertical available — a display company can hold exclusive rights without affecting medical device or lighting licensing tracks.
Full synthesis protocols, structural characterization data, and emission performance data available under executed NDA. Contact David Conway directly to request.
Hypoxia-responsive Zr-AZB MOF. Cisplatin-validated. 8.8× selectivity.
Learn more →Cu(I) phosphorescent sensors. 85% O₂ quenching. Narcan auto-release.
Learn more →6 MOF formula families. ZIFs, MOF-74, NHC complexes. Industrial CCS.
Learn more →Gd/Hf/Zr/ZIF frameworks. Radiation shielding, Mars ISRU, life support.
Learn more →Lanthanide/Zr/Zn luminescent MOFs. Tunable visible and NIR emission.
Current page